Rheumatology
Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.
Recent Discussions
Are the results of the SEAM-RA trial generalizable to other TNF inhibitors given the differences in immunogenicity?
This is a great question, and an important one because different TNF inhibitors have different immunogenicity and patients can make anti-drug antibodies that can effectively neutralize the drug and render it a less effective treatment option. This tends to happen more with some molecular constructs ...
How long would you recommend that a patient continues guselkumab prior to deciding that the therapy is not effective?
Many trials have a placebo-controlled period of 12-24 weeks. Thereafter, all patients receive active treatment. Even if the original treatment allocation remains unknown to the patient and doctor, they know that from that moment on, everyone receives active treatment. This will have an influence on ...
How would you treat SLE (inflammatory arthritis, +ANA/dsDNA/SSA) overlap with RA (CCP high titer) in a young female of childbearing age with low TPMT?
Age and gender should not restrict this or any patient from standard of care medication(s) for arthritis. Methotrexate or leflunomide are first line therapies here. As a Medpeds Rheumatologist, we do not avoid methotrexate in teens or young adults because of their potential risks, unless specificall...
In the setting of new onset severe Raynaud’s with digital ischemia (partial toe amputation), but negative initial rheumatologic evaluation, what additional rheumatologic or hematologic workup should be considered?
This is always a difficult situation. As Rheumatologists, we tend to lean hard on the laboratories, but in cases like this, it is the history and physical examination that tell the better story. The history is critical here, since a smoking/tobacco history gives a lot of information. Any history of ...
How do you interpret treatment response in the DISCOVER-2 Trial when patients were allowed to remain on up to 10mg of prednisone equivalent for disease control while on guselkumab?
The dependence on the use of systemic glucocorticoids may indeed be a good reason to change treatment. Especially in patients with psoriatic arthritis. So, if patients are unable to stop systemic glucocorticoids and there are still treatment options for the patient, this could be tried. It is diffic...
What is your experience with using extended release intra-articular steroid preparations, such as Zilretta in patients with osteoarthritis?
Intra-articular glucocorticoids have been used for decades to treat painful knee osteoarthritis. In the past, steroid preparations of relatively insoluble crystals such as triamcinolone hexacetonide were used with the intention of prolonging the duration of intraarticular action. Although the retent...
How do you manage worsening cutaneous dermatomyositis when muscle disease appears controlled?
The fact that the patient still has an active pruritic rash while tapering steroids suggests that the current regimen isn't fully controlling the disease, and it can affect quality of life. I would consider adjusting immunosuppression, either adding another agent or switching therapies. The specific...
Do you routinely recommend antibiotic prophylaxis for routine dental cleaning in patients taking mycophenolate mofetil?
The most recent AHA and ADA guidelines continue to recommend antibiotic prophylaxis prior to dental procedures for patients at high risk of developing endocarditis (Goff et al., PMID 31728507). Additional recommendations from the ADA include avoiding routine dental care for the first 6 months after ...
Do you recommend allopurinol desensitization in gout patients who develop a rash on allopurinol therapy?
I don't recommend desensitization for allopurinol-allergic patients. There was a time when this made sense due to the lack of a viable alternative therapy. The process is cumbersome in a private practice setting and not as simple as providing the patient with a prescription for febuxostat.Febuxostat...
Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?
Once Avacopan is available for clinical use in the treatment of patients with AAV, providers will need to carefully weigh risks and benefits of the medication while considering other factors including cost.The ADVOCATE trial used a novel glucocorticoid toxicity index that captures common GC-related ...